糖皮质激素抵抗在耳鼻咽喉疾病中的研究进展  

Advances in glucocorticoid resistance in otorhinolaryngological diseases

作　　者：李亚秀 佘万东[1] LI Yaxiu;SHE Wandong(Department of Otorhinolaryngology,Head and Neck Surgery,Nanjing Drum Tower Hospital Clinical College of Nanjing Medical University,Nanjing,210008,China)

机构地区：[1]南京医科大学鼓楼临床医学院耳鼻咽喉头颈外科,南京210008

出　　处：《临床耳鼻咽喉头颈外科杂志》2024年第7期661-665,共5页Journal of Clinical Otorhinolaryngology Head And Neck Surgery

基　　金：国家自然科学基金(No:81670931);南京市医学重点科技发展项目(No:ZKX-21012);江苏省自然科学基金(No:BK20231122);南京鼓楼医院临床研究专项资金面上项目:(No:2022-LCYJ-NMS-01)。

摘　　要：糖皮质激素(glucocorticoids,GC)临床上广泛应用于自身免疫性内耳病、突发性聋、梅尼埃病及鼻窦炎等耳鼻咽喉疾病的治疗,部分患者存在GC抵抗现象,但导致GC抵抗因素机制尚不清楚,本文从GC受体因素和非GC受体因素两方面阐述了GC抵抗的相关机制,并综述其在耳鼻咽喉科疾病的最新研究进展,旨在未来寻找GC抵抗生物标志物,提高GC疗效提出新策略。Glucocorticoids(GC)are widely used in the clinical treatment of autoimmune inner ear diseases,sudden sensorineural hearing loss,Meniere's disease,sinusitis and other otolaryngology diseases.However,GC resistance remains a major factor contributing to the poor efficacy of clinical treatments.The mechanism of GC resistance is still unclear.This paper reviews the related mechanisms of GC resistance from the perspectives of GC receptor factors and non-GC receptor factors.Additionally,it summarizes the latest research progress on GC resistance in otolaryngological diseases,with the aim of identifying effective clinical alternative treatment options for reversing GC resistance in the future.

关 键 词：糖皮质激素抵抗 糖皮质激素 糖皮质激素受体 突发性聋 鼻窦炎 

分 类 号：R764.43[医药卫生—耳鼻咽喉科]